{"title":"[细菌肽聚糖生物合成酶抑制剂的研究进展]。","authors":"Fan Liu, Hao-yi Meng, Zheng-yang Sun, Dan-yang Li, Yuan-yuan Jin, Zhao-yong Yang, Shao-jie Wu, Jing Chen","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains\nbecame a serious threat to public health. This status demands development of new antibacterial agents with\nnovel mechanisms of action. The reason for the limited new antibacterials is the small number of effective\ntherapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for\nnew targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component\nof the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical\npathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for\nthe development of new classes of antibacterial agents. This review provides an in-depth insight into the recent\ndevelopments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of\ncandidate inhibitors and the challenges to overcome the hurdles are also discussed.</p>","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"52 3","pages":"362-70"},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis].\",\"authors\":\"Fan Liu, Hao-yi Meng, Zheng-yang Sun, Dan-yang Li, Yuan-yuan Jin, Zhao-yong Yang, Shao-jie Wu, Jing Chen\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains\\nbecame a serious threat to public health. This status demands development of new antibacterial agents with\\nnovel mechanisms of action. The reason for the limited new antibacterials is the small number of effective\\ntherapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for\\nnew targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component\\nof the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical\\npathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for\\nthe development of new classes of antibacterial agents. This review provides an in-depth insight into the recent\\ndevelopments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of\\ncandidate inhibitors and the challenges to overcome the hurdles are also discussed.</p>\",\"PeriodicalId\":35924,\"journal\":{\"name\":\"药学学报\",\"volume\":\"52 3\",\"pages\":\"362-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药学学报\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Advances in the research of inhibitors of enzymes of bacterial peptidoglycan biosynthesis].
In recent years, owing to the abuse of antibiotics, the widespread of resistant bacterial strains
became a serious threat to public health. This status demands development of new antibacterial agents with
novel mechanisms of action. The reason for the limited new antibacterials is the small number of effective
therapeutic targets, which cannot meet the current needs for the multiple drug-resistant treatment. Screening for
new targets is the key step in the development of novel antibacterial agents. Peptidoglycan is the main component
of the cell wall of bacteria, which is essential for survival of pathogenic bacteria. Within the biochemical
pathway for peptidoglycan biosynthes is the Murligases, described in this review as highly potential targets for
the development of new classes of antibacterial agents. This review provides an in-depth insight into the recent
developments in the field of inhibitors of the Mur enzymes (MurA-F). Moreover, the reasons for the lack of
candidate inhibitors and the challenges to overcome the hurdles are also discussed.
药学学报Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.20
自引率
0.00%
发文量
0
期刊介绍:
Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.